Envveno Medical Corp. sell nvestor
Start price
12.12.20
/
50%
€10.03
Target price
12.12.21
€4.00
Performance (%)
-45.01%
End price
26.06.21
€5.52
Summary
This prediction ended on 26.06.21 with a price of €5.52. nvestor correctly predicted massive losses of -45.01% for Envveno Medical Corp.. nvestor has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Envveno Medical Corp. | 6.522% | 6.522% | 33.880% | -1.863% |
| iShares Core DAX® | 0.961% | -2.210% | 12.839% | 17.154% |
| iShares Nasdaq 100 | 2.626% | -1.918% | 38.498% | 45.463% |
| iShares Nikkei 225® | 0.217% | -7.216% | 19.425% | 5.076% |
| iShares S&P 500 | 1.540% | -1.858% | 27.801% | 42.583% |
According to nvestor what are the pros and cons of Envveno Medical Corp. for the foreseeable future?
Pros
Cons
Risky Investment
Revenue decline > 20% expected
EBIT decline > 20% expected
Decining EBIT margin than peer group
overvalued
Very low/no dividend yield expected
very negative Cash Flow expected
Junk rating
Very little Investments for future growth
High risks in the balance sheet
ROE lower than 5% per year
High challenges to pay loans and raise capital
Deficits in Management
Very bad culture
No Innovation
No uniques
Dependend from few customers or products
Growths much slower than the competition
Sustainability is not important
Mainly gamblers invest here
High risks for its business
Nicheplayer
Very high cyclical dependencies
Unknown brand
Outdated or very high risk business model